SMS Pharmaceuticals Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y4qmmik8otqzz88yq94w27bf.pdf

Key Takeaways


Growth Drivers & Product Performance


Margin & Cost Strategy

Vamsi Krishna Potluri: "the only control that we currently have with us is backward integration. So, that is the reason this year, as it was explained in the call, I think majority of the focus that we are giving is backward integrating into critical, most of our KSMs for most of our critical products."

Industry & Pricing Environment

Vamsi Krishna Potluri: "for the next 6 months it will be a consolidation mode. I think people, there will be a lot of price pressure and volatility will be there for the next 6 months to 9 months, post that I think it will probably settle down once the consolidation phase happens."

Capital Allocation & Capacity


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthMid-teens growthFY25
EBITDA margin18% to 20%FY25
Export growth10% to 15% growth rateGoing forward
US DMF filingsMinimum of 10 drug master filesUpcoming fiscal year
CAPEX plan disclosureDetailed CAPEX plans to be sharedNear future
New facility timeline6 to 8 months including validationsFrom CAPEX initiation

Key Metrics

MetricQ3 FY24
Revenue growth9% YoY; 24% YoY for 9M FY24
API segment revenue₹160.3 cr; 9M FY24: ₹456.1 cr
API share of consolidated revenue99.3%; 98.4% for 9M FY24
EBITDA₹29 cr, up 57% YoY
PAT₹11.5 cr, up 205% YoY
FY25 revenue growth guidanceMid-teens growth
FY25 EBITDA margin guidance18% to 20%
Capacity utilization65% to 70%, up from 50–55% in prior quarters
Ibuprofen capacity utilization~50%
API export share88% of API revenue, including deemed exports
API domestic share12% of API revenue
Anti-retroviral share of sales33% of total sales
Anti-inflammatory share of sales18% of total sales
Anti-diabetic share of sales13% of total sales
Anti-migraine share of sales13% of total sales
Top 5 products volume growth15% to 20% YoY
Fundraising via warrants₹114.3 cr, at ₹127 per warrant
Warrant funds allocation to CAPEX55%
Warrant funds allocation to working capital35%